Cardiotoxic Drugs in Breast Cancer [2]

Journal of the National Medical Association

Volumn 96, Issue 5, 2004, Pages 690-691

  Sevinc, Alper ^a   Buyukberber, Suleyman ^a   Camci, Celalettin ^a  

^a GAZIANTEP UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DOXORUBICIN; PACLITAXEL; TRASTUZUMAB;

BREAST CANCER; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; DRUG POTENTIATION; HEART LEFT VENTRICLE FUNCTION; HUMAN; LETTER; PRIORITY JOURNAL; RISK FACTOR;

AFRICAN AMERICANS; BREAST NEOPLASMS; DOXORUBICIN; DRUG THERAPY, COMBINATION; HEART DISEASES; HUMANS; PACLITAXEL; RISK FACTORS;

EID: 2342419707     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Hasan S, Dinh D, Lombardo F, et al. Doxorubicin cardiotoxicity in African Americans. J Natl Med Assoc. 2004;96:196-199.
2. Perez EA. Paclitaxel and cardiotoxicity. J Clin Oncol. 1998;16:3481-3482.
3. Ewer MS, Gibbs HR, Swafford J, et al. Cardiotoxicity in patients receiving transtuzomab (Herceptin): primary toxicity, synergistic, or sequential stress, or surveillance artifact? Semin Oncol. 1999;26(4 Suppl 12):96-101.
4. Jerian S, Keegan P. Cardiotoxicity associated with paclitaxel/ trastuzumab combination therapy. J Clin Oncol. 1999;17:1647-1648.
5. Lefrak EA, Pitha J, Rosenheim S, et al. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973;32:302-314.